Traws Pharma (TRAW) Change in Accured Expenses (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Change in Accured Expenses of $50000.0 for Q1 2026, up 108.31% year-over-year from $24003.2 in Q1 2025, and down 98.16% quarter-over-quarter from $2.7 million in Q4 2025.
Traws Pharma (TRAW) Change in Accured Expenses (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Change in Accured Expenses for 15 consecutive years, with $50000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 108.31% year-over-year to $50000.0; the TTM figure through Mar 2026 stood at $3.0 million (up 159.6% YoY), while the FY2025 annual figure was $2.4 million, up 145.45% from the prior year.
- Change in Accured Expenses fell to $50000.0 in Q1 2026 per TRAW's latest filing, from $2.7 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.7 million in Q4 2025 and bottomed at -$4.1 million in Q2 2024.
- Historically, Change in Accured Expenses has averaged -$150235.3 across 5 years, with a median of $74000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 589.15% — and 2024, when it tumbled 1144.93%.
- Traws Pharma's Change in Accured Expenses stood at $610000.0 in 2022, then plunged by 87.7% to $75000.0 in 2023, then jumped by 528.0% to $471000.0 in 2024, then surged by 475.58% to $2.7 million in 2025, then sank by 98.16% to $50000.0 in 2026.
- Business Quant data shows TRAW's Change in Accured Expenses at $50000.0 in Q1 2026, $2.7 million in Q4 2025, and $189000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | -2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50,000.00 |
| Mar 31, 2026 | 50,000.00 |
| Dec 31, 2025 | 2.71 Mn |
| Dec 31, 2025 | 2.71 Mn |
| Sep 30, 2025 | 189,000.00 |
| Sep 30, 2025 | 189,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Jun 30, 2025 | 74,000.00 |
| Mar 31, 2025 | -602,000.00 |
| Mar 31, 2025 | -602,000.00 |
| Dec 31, 2024 | 471,000.00 |
| Dec 31, 2024 | 471,000.00 |
| Sep 30, 2024 | -859,000.00 |
| Sep 30, 2024 | -859,000.00 |
| Jun 30, 2024 | -4.08 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -747,000.00 |
| Mar 31, 2024 | -747,000.00 |
| Dec 31, 2023 | 75,000.00 |
| Dec 31, 2023 | 75,000.00 |